Korro Bio (KRRO) Non Operating Investment Income (2019 - 2022)
Korro Bio's (KRRO) quarterly Non Operating Investment Income came in at $1000.0 in Q3 2022, up 111.11% YoY from $473.68 in Q3 2021, and down 50.0% on a QoQ basis from $2000.0 in Q2 2022.
Korro Bio (KRRO) Non Operating Investment Income (2019 - 2022) Analysis & Trends
Korro Bio (KRRO) has 4 years of Non Operating Investment Income data on file, last reported at $1000.0 in Q3 2022.
- Quarterly Non Operating Investment Income rose 111.11% year-over-year to $1000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $3000.0 (up 113.04% YoY) and the FY2022 annual result came in at $3000.0, up 113.04% from the prior year.
- Non Operating Investment Income slipped to $1000.0 in Q3 2022, from $2000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $69000.0 in Q1 2020 to a low of -$10000.0 in Q2 2021.
- A 4-year average of $18363.6 and a median of $2000.0 in 2022 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2021 — Non Operating Investment Income sank 150.0% — and 2022, when it soared 120.0%.
- Tracing KRRO's Non Operating Investment Income over 4 years: stood at $50000.0 in 2019, then plunged by 62.0% to $19000.0 in 2020, then sank by 147.37% to -$9000.0 in 2021, then jumped by 111.11% to $1000.0 in 2022.
- The last three Non Operating Investment Income figures came in at $1000.0 (Q3 2022), $2000.0 (Q2 2022), and -$9000.0 (Q3 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 2,000.00 |
| Sep 30, 2021 | -9,000.00 |
| Sep 30, 2021 | -9,000.00 |
| Jun 30, 2021 | -10,000.00 |
| Jun 30, 2021 | -10,000.00 |
| Mar 31, 2021 | -4,000.00 |
| Mar 31, 2021 | -4,000.00 |
| Dec 31, 2020 | 19,000.00 |
| Dec 31, 2020 | 19,000.00 |
| Jun 30, 2020 | -4,000.00 |
| Jun 30, 2020 | -4,000.00 |
| Mar 31, 2020 | 69,000.00 |
| Mar 31, 2020 | 69,000.00 |
| Dec 31, 2019 | 50,000.00 |
| Dec 31, 2019 | 50,000.00 |
| Sep 30, 2019 | 62,000.00 |
| Sep 30, 2019 | 62,000.00 |